Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Payables (2018 - 2025)

BioNexus Gene Lab's Payables history spans 8 years, with the latest figure at $401611.0 for Q4 2025.

  • Quarterly results put Payables at $401611.0 for Q4 2025, up 41.36% from a year ago — trailing twelve months through Dec 2025 was $401611.0 (up 41.36% YoY), and the annual figure for FY2025 was $401611.0, up 41.36%.
  • Payables for Q4 2025 was $401611.0 at BioNexus Gene Lab, up from $375380.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.9 million in Q4 2022 to a low of $29776.0 in Q3 2023.
  • The 5-year median for Payables is $232510.0 (2023), against an average of $556985.4.
  • The sharpest move saw Payables soared 4693.16% in 2022, then tumbled 97.95% in 2023.
  • Year by year, Payables stood at $71814.0 in 2021, then soared by 2491.44% to $1.9 million in 2022, then plummeted by 90.28% to $180912.0 in 2023, then soared by 57.04% to $284108.0 in 2024, then surged by 41.36% to $401611.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $401611.0, $375380.0, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.